Aurobindo Pharma's United States subsidiary, Aurobindo Pharma USA, confirmed on Tuesday that it has received final approval from the US Food and Drug Administration for Glycerol Phenylbutyrate Oral Liquid, the generic equivalent of Hyperion Therapeutics' branded drug Ravicti. The approval, which follows the USFDA nod reported Monday, clears the company to begin commercial distribution in the United States market, where Ravicti generates estimated annual revenues of approximately $200 million.

Glycerol Phenylbutyrate is indicated as a nitrogen-binding agent for chronic management of adult and paediatric patients with urea cycle disorders, a rare but life-threatening group of genetic conditions that prevent the body from processing protein waste. The drug reduces ammonia accumulation in the blood, which can cause neurological damage or death if left untreated. Ravicti, the reference product, is currently marketed by Immedica Pharma following a series of acquisitions.

Aurobindo's approval is expected to introduce meaningful price competition in a market that has seen limited generic entry due to the complexity of the formulation and the specialised patient population. Analysts at brokerage firms covering Indian pharmaceutical exporters noted that first-mover generic advantage in orphan-drug adjacent categories can be commercially significant, even at lower price points than the branded counterpart.

The Hyderabad-based company, one of India's largest pharmaceutical exporters by volume, has been steadily expanding its US generics portfolio across complex dosage forms including injectables and liquid formulations. The glycerol phenylbutyrate approval adds to a string of recent USFDA clearances and reinforces Aurobindo's strategy of targeting technically demanding products where competition remains thin.

Patient advocacy groups in the rare disease community welcomed the development, noting that increased generic availability could reduce out-of-pocket costs for families managing urea cycle disorders long-term. Aurobindo is expected to confirm a commercial launch timeline for the US market within the coming weeks, subject to manufacturing readiness at its FDA-inspected facility.